{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT04077099",
      "OrgStudyIdInfo": {
        "OrgStudyId": "R5093-ONC-1863"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "2019-001908-38",
            "SecondaryIdType": "EudraCT Number"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "Regeneron Pharmaceuticals",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer",
      "OfficialTitle": "A Phase 1/2 Study of REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer"
    },
    "StatusModule": {
      "StatusVerifiedDate": "October 2021",
      "OverallStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "January 7, 2020",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "October 20, 2024",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "October 20, 2024",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "August 13, 2019",
      "StudyFirstSubmitQCDate": "August 29, 2019",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "September 4, 2019",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "October 28, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "October 29, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Regeneron Pharmaceuticals",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No",
      "IsFDARegulatedDrug": "Yes",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The primary objective of the dose escalation (phase 1) part of the study is to assess the safety, tolerability, and pharmacokinetics (PK) of REGN5093 for determination of the maximum tolerated dose (MTD) and/or definition of the recommended phase 2 dose (RP2D) of REGN5093 in patients with MET-altered Non-small cell lung cancer (NSCLC).\n\nThe primary objective of the dose expansion (phase 2) part of the study is to assess preliminary anti-tumor activity of REGN5093 as measured by the objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1)"
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "NSCLC"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "MET (mesenchymal-epithelial transition factor)",
          "HGF (Hepatocyte Growth Factor)",
          "NSCLC (non-small cell lung cancer)",
          "MET-altered advanced",
          "Unresectable",
          "Metastatic disease"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "111",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "REGN5093",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Monotherapy in dose escalation cohorts (phase 1) followed by an expansion phase (phase 2)",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: REGN5093"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "REGN5093",
            "InterventionDescription": "Intravenous (IV) infusion. There will be a series of dose escalation cohorts followed by an expansion phase.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "REGN5093"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Number of patients with Dose Limiting Toxicities",
            "PrimaryOutcomeDescription": "Phase 1/Dose escalation",
            "PrimaryOutcomeTimeFrame": "Up to 21 days"
          },
          {
            "PrimaryOutcomeMeasure": "Incidence and severity of treatment-emergent adverse events",
            "PrimaryOutcomeDescription": "Phase 1/Dose escalation",
            "PrimaryOutcomeTimeFrame": "Through study completion, an average of 4 years"
          },
          {
            "PrimaryOutcomeMeasure": "Incidence and severity of adverse events of special interest (AESIs)",
            "PrimaryOutcomeDescription": "Phase 1/Dose escalation",
            "PrimaryOutcomeTimeFrame": "Through study completion, an average of 4 years"
          },
          {
            "PrimaryOutcomeMeasure": "Incidence and severity of serious adverse events (SAEs)",
            "PrimaryOutcomeDescription": "Phase 1/Dose escalation",
            "PrimaryOutcomeTimeFrame": "Through study completion, an average of 4 years"
          },
          {
            "PrimaryOutcomeMeasure": "Incidence and severity of grade ≥3 laboratory abnormalities",
            "PrimaryOutcomeDescription": "Phase 1/Dose escalation",
            "PrimaryOutcomeTimeFrame": "Through study completion, an average of 4 years"
          },
          {
            "PrimaryOutcomeMeasure": "REGN5093 concentrations in serum over time",
            "PrimaryOutcomeDescription": "Phase 1/Dose escalation",
            "PrimaryOutcomeTimeFrame": "Through study completion, an average of 4 years"
          },
          {
            "PrimaryOutcomeMeasure": "Objective response rate (ORR) per RECIST 1.1",
            "PrimaryOutcomeDescription": "Phase 2/Dose expansion",
            "PrimaryOutcomeTimeFrame": "Through study completion, an average of 4 years"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "ORR per RECIST 1.1",
            "SecondaryOutcomeDescription": "Phase 1/Dose escalation",
            "SecondaryOutcomeTimeFrame": "Through study completion, an average of 4 years"
          },
          {
            "SecondaryOutcomeMeasure": "Incidence and severity of TEAEs",
            "SecondaryOutcomeDescription": "Phase 2/Dose expansion",
            "SecondaryOutcomeTimeFrame": "Through study completion, an average of 4 years"
          },
          {
            "SecondaryOutcomeMeasure": "Incidence and severity of AESIs",
            "SecondaryOutcomeDescription": "Phase 2/Dose expansion",
            "SecondaryOutcomeTimeFrame": "Through study completion, an average of 4 years"
          },
          {
            "SecondaryOutcomeMeasure": "Incidence and severity of SAEs",
            "SecondaryOutcomeDescription": "Phase 2/Dose expansion",
            "SecondaryOutcomeTimeFrame": "Through study completion, an average of 4 years"
          },
          {
            "SecondaryOutcomeMeasure": "Incidence and severity of grade ≥3 laboratory abnormalities",
            "SecondaryOutcomeDescription": "Phase 2/Dose expansion",
            "SecondaryOutcomeTimeFrame": "Through study completion, an average of 4 years"
          },
          {
            "SecondaryOutcomeMeasure": "REGN5093 Pharmacokinetics (PK)",
            "SecondaryOutcomeDescription": "Phase 2/Dose expansion",
            "SecondaryOutcomeTimeFrame": "Through study completion, an average of 4 years"
          },
          {
            "SecondaryOutcomeMeasure": "REGN5093 concentrations in serum over time",
            "SecondaryOutcomeDescription": "Phase 2/Dose expansion",
            "SecondaryOutcomeTimeFrame": "Through study completion, an average of 4 years"
          },
          {
            "SecondaryOutcomeMeasure": "Duration of response (DOR) per RECIST 1.1.",
            "SecondaryOutcomeDescription": "Phase 1 and 2",
            "SecondaryOutcomeTimeFrame": "Through study completion, an average of 4 years"
          },
          {
            "SecondaryOutcomeMeasure": "Disease control rate (DCR) per RECIST 1.1.",
            "SecondaryOutcomeDescription": "Phase 1 and 2",
            "SecondaryOutcomeTimeFrame": "Through study completion, an average of 4 years"
          },
          {
            "SecondaryOutcomeMeasure": "Progression free survival (PFS) per RECIST 1.1.",
            "SecondaryOutcomeDescription": "Phase 1 and 2",
            "SecondaryOutcomeTimeFrame": "Through study completion, an average of 4 years"
          },
          {
            "SecondaryOutcomeMeasure": "Overall survival (OS)",
            "SecondaryOutcomeDescription": "Phase 1 and 2",
            "SecondaryOutcomeTimeFrame": "Through study completion, an average of 4 years"
          },
          {
            "SecondaryOutcomeMeasure": "Immunogenicity as measured by Anti-drug antibodies (ADA) to REGN5093",
            "SecondaryOutcomeDescription": "Phase 1 and 2",
            "SecondaryOutcomeTimeFrame": "Through study completion, an average of 4 years"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Key Inclusion Criteria:\n\nHistologically confirmed NSCLC that is at advanced stage. Advanced is defined as unresectable or metastatic disease. Patients must have exhausted all approved available therapies appropriate for the patient.\nHas available archival tumor tissue, unless discussed with the medical monitor.\nWilling to provide tumor tissue from newly obtained biopsy. Newly obtained biopsies at screening are required unless medically contra-indicated and discussed with the medical monitor. For patients in expansion cohorts, biopsies should be taken from tumor site which has not been irradiated previously and is not the only measurable target lesion.\nPreviously documented presence of MET alterations: either MET-exon14 gene mutation and/or MET gene amplification, and/or elevated MET protein expression, as defined in the protocol.\n\nKey Exclusion Criteria:\n\nHas received treatment with an approved systemic therapy or has participated in any study of an investigational agent or investigational device within 2 weeks or 5 half-lives of the prior treatment whichever is shorter with a minimum of 7 days from the first dose of study therapy\nHas not yet recovered (i.e. grade ≤1 or baseline) from any acute toxicities resulting from prior therapy except as described in the protocol\nHas received radiation therapy or major surgery within 14 days of first administration of study drug or has not recovered (i.e. grade ≤1 or baseline) from AEs, except for laboratory changes as described in the protocol and patients with grade ≤2 neuropathy\nFor expansion cohorts only: prior treatment with MET-targeted biologic therapy (function-blocking antibodies or ADCs)\nFor expansion cohorts only (except cohort 1A) prior treatment with any MET-targeted agent including small molecule tyrosine kinase inhibitors eg, crizotinib, capmatinib, tepotinib, as defined in the protocol\nUntreated or active primary brain tumor, CNS metastases, leptomeningeal disease or spinal cord compression as defined in the protocol\n\nNote: Other protocol defined Inclusion/Exclusion criteria apply.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Clinical Trials Administrator",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "844-734-6643",
            "CentralContactEMail": "clinicaltrials@regeneron.com"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Clinical Trial Management",
            "OverallOfficialAffiliation": "Regeneron Pharmaceuticals",
            "OverallOfficialRole": "Study Director"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Regeneron Research Facility",
            "LocationStatus": "Recruiting",
            "LocationCity": "Birmingham",
            "LocationState": "Alabama",
            "LocationZip": "35294",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Regeneron Research Facility",
            "LocationStatus": "Recruiting",
            "LocationCity": "Orange",
            "LocationState": "California",
            "LocationZip": "92868",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Regeneron Research Facility",
            "LocationStatus": "Recruiting",
            "LocationCity": "Washington",
            "LocationState": "District of Columbia",
            "LocationZip": "20007",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Regeneron Research Facility",
            "LocationStatus": "Recruiting",
            "LocationCity": "Tampa",
            "LocationState": "Florida",
            "LocationZip": "33612",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Regeneron Research Facility",
            "LocationStatus": "Recruiting",
            "LocationCity": "Lexington",
            "LocationState": "Kentucky",
            "LocationZip": "40536",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Regeneron Research Facility",
            "LocationStatus": "Recruiting",
            "LocationCity": "Boston",
            "LocationState": "Massachusetts",
            "LocationZip": "02215",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Regeneron Research Facility",
            "LocationStatus": "Recruiting",
            "LocationCity": "Detroit",
            "LocationState": "Michigan",
            "LocationZip": "48202",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Regeneron Research Facility",
            "LocationStatus": "Recruiting",
            "LocationCity": "Saint Louis",
            "LocationState": "Missouri",
            "LocationZip": "63110",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Regeneron Research Facility",
            "LocationStatus": "Recruiting",
            "LocationCity": "New York",
            "LocationState": "New York",
            "LocationZip": "10016",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Regeneron Research Facility",
            "LocationStatus": "Recruiting",
            "LocationCity": "New York",
            "LocationState": "New York",
            "LocationZip": "10029",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Regeneron Research Facility",
            "LocationStatus": "Recruiting",
            "LocationCity": "New York",
            "LocationState": "New York",
            "LocationZip": "10065",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Regeneron Research Facility",
            "LocationStatus": "Completed",
            "LocationCity": "Durham",
            "LocationState": "North Carolina",
            "LocationZip": "27710",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Regeneron Research Facility",
            "LocationStatus": "Completed",
            "LocationCity": "Oklahoma City",
            "LocationState": "Oklahoma",
            "LocationZip": "73104",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Regeneron Research Facility",
            "LocationStatus": "Recruiting",
            "LocationCity": "Philadelphia",
            "LocationState": "Pennsylvania",
            "LocationZip": "19111",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Regeneron Research Facility",
            "LocationStatus": "Recruiting",
            "LocationCity": "Pittsburgh",
            "LocationState": "Pennsylvania",
            "LocationZip": "15232",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Regeneron Research Facility",
            "LocationStatus": "Recruiting",
            "LocationCity": "Dallas",
            "LocationState": "Texas",
            "LocationZip": "75390",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Regeneron Research Facility",
            "LocationStatus": "Recruiting",
            "LocationCity": "Houston",
            "LocationState": "Texas",
            "LocationZip": "77030",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Regeneron Research Facility",
            "LocationStatus": "Recruiting",
            "LocationCity": "Bordeaux Cedex 9",
            "LocationZip": "33076",
            "LocationCountry": "France"
          },
          {
            "LocationFacility": "Regeneron Research Facility",
            "LocationStatus": "Recruiting",
            "LocationCity": "Dijon Cedex",
            "LocationZip": "21034",
            "LocationCountry": "France"
          },
          {
            "LocationFacility": "Regeneron Research Facility",
            "LocationStatus": "Recruiting",
            "LocationCity": "Grenoble",
            "LocationZip": "38043",
            "LocationCountry": "France"
          },
          {
            "LocationFacility": "Regeneron Research Facility",
            "LocationStatus": "Recruiting",
            "LocationCity": "Montpellier",
            "LocationZip": "34295",
            "LocationCountry": "France"
          },
          {
            "LocationFacility": "Regeneron Research Facility",
            "LocationStatus": "Recruiting",
            "LocationCity": "Rennes Cedex 9",
            "LocationZip": "35033",
            "LocationCountry": "France"
          },
          {
            "LocationFacility": "Regeneron Research Facility",
            "LocationStatus": "Recruiting",
            "LocationCity": "Gyeonggi do",
            "LocationState": "Gyeonggi",
            "LocationZip": "10408",
            "LocationCountry": "Korea, Republic of"
          },
          {
            "LocationFacility": "Regeneron Research Facility",
            "LocationStatus": "Recruiting",
            "LocationCity": "Suwon",
            "LocationState": "Gyeonggi",
            "LocationZip": "16247",
            "LocationCountry": "Korea, Republic of"
          },
          {
            "LocationFacility": "Regeneron Research Facility",
            "LocationStatus": "Recruiting",
            "LocationCity": "Seoul",
            "LocationZip": "03080",
            "LocationCountry": "Korea, Republic of"
          },
          {
            "LocationFacility": "Regeneron Research Facility",
            "LocationStatus": "Recruiting",
            "LocationCity": "Seoul",
            "LocationZip": "03722",
            "LocationCountry": "Korea, Republic of"
          },
          {
            "LocationFacility": "Regeneron Research Facility",
            "LocationStatus": "Recruiting",
            "LocationCity": "Seoul",
            "LocationZip": "05505",
            "LocationCountry": "Korea, Republic of"
          },
          {
            "LocationFacility": "Regeneron Research Facility",
            "LocationStatus": "Recruiting",
            "LocationCity": "Seoul",
            "LocationZip": "06351",
            "LocationCountry": "Korea, Republic of"
          },
          {
            "LocationFacility": "Regeneron Research Facility",
            "LocationStatus": "Recruiting",
            "LocationCity": "Seoul",
            "LocationZip": "06591",
            "LocationCountry": "Korea, Republic of"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "Yes",
      "IPDSharingDescription": "All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing",
      "IPDSharingInfoTypeList": {
        "IPDSharingInfoType": [
          "Study Protocol",
          "Statistical Analysis Plan (SAP)",
          "Informed Consent Form (ICF)",
          "Clinical Study Report (CSR)",
          "Analytic Code"
        ]
      },
      "IPDSharingTimeFrame": "Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.",
      "IPDSharingAccessCriteria": "Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, EMA, PMDA, etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).",
      "IPDSharingURL": "https://vivli.org/"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000008175",
            "ConditionMeshTerm": "Lung Neoplasms"
          },
          {
            "ConditionMeshId": "D000002289",
            "ConditionMeshTerm": "Carcinoma, Non-Small-Cell Lung"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000012142",
            "ConditionAncestorTerm": "Respiratory Tract Neoplasms"
          },
          {
            "ConditionAncestorId": "D000013899",
            "ConditionAncestorTerm": "Thoracic Neoplasms"
          },
          {
            "ConditionAncestorId": "D000009371",
            "ConditionAncestorTerm": "Neoplasms by Site"
          },
          {
            "ConditionAncestorId": "D000009369",
            "ConditionAncestorTerm": "Neoplasms"
          },
          {
            "ConditionAncestorId": "D000008171",
            "ConditionAncestorTerm": "Lung Diseases"
          },
          {
            "ConditionAncestorId": "D000012140",
            "ConditionAncestorTerm": "Respiratory Tract Diseases"
          },
          {
            "ConditionAncestorId": "D000002283",
            "ConditionAncestorTerm": "Carcinoma, Bronchogenic"
          },
          {
            "ConditionAncestorId": "D000001984",
            "ConditionAncestorTerm": "Bronchial Neoplasms"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M10324",
            "ConditionBrowseLeafName": "Lung Neoplasms",
            "ConditionBrowseLeafAsFound": "Lung Cancer",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M4698",
            "ConditionBrowseLeafName": "Carcinoma, Non-Small-Cell Lung",
            "ConditionBrowseLeafAsFound": "Non-Small Cell Lung Cancer",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M11459",
            "ConditionBrowseLeafName": "Neoplasm Metastasis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4686",
            "ConditionBrowseLeafName": "Carcinoma",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14131",
            "ConditionBrowseLeafName": "Respiratory Tract Neoplasms",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M15810",
            "ConditionBrowseLeafName": "Thoracic Neoplasms",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10320",
            "ConditionBrowseLeafName": "Lung Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14129",
            "ConditionBrowseLeafName": "Respiratory Tract Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4692",
            "ConditionBrowseLeafName": "Carcinoma, Bronchogenic",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4412",
            "ConditionBrowseLeafName": "Bronchial Neoplasms",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC08",
            "ConditionBrowseBranchName": "Respiratory Tract (Lung and Bronchial) Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M11052",
            "InterventionBrowseLeafName": "Mitogens",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}